SCHEMBL12848312

SCHEMBL12848312

CC(C)Nc1cccc(O)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.40
FDFT1 P37268 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
HCAR3 P49019 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
IDO1 P14902 2/20 0.36
KCNH3 Q9ULD8 1/20 0.36
FLT3 P36888 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
XIAP P98170 1/20 0.35
BIRC2 Q13490 1/20 0.35
ALDH1A1 P00352 3/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12541310 0.84 TDP1 (0.44) FDPSFDFT1SMN1; SMN2HCAR3TDP1
SCHEMBL17198269 0.79 FDPS (0.36) FDPSFDFT1SMN1; SMN2TDP1ALDH1A1
SCHEMBL14270726 0.77 FDPS (0.58) FDPSFDFT1SMN1; SMN2ALDH1A1MEN1
SCHEMBL12848276 0.76
SCHEMBL8001028 0.75 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2AGAA
SCHEMBL22332344 0.75 FFAR2 (0.43) FDPSFDFT1SMN1; SMN2TDP1KCNH3
SCHEMBL3224012 0.75 XIAP (0.54) FDPSFDFT1TDP1KCNH3FLT3
SCHEMBL21323398 0.75 TDP1 (0.37) FDPSFDFT1SMN1; SMN2HCAR3TDP1
SCHEMBL17658884 0.75 HSD11B1 (0.41) FDPSFDFT1SMN1; SMN2HCAR3TDP1
SCHEMBL10829373 0.75 KDR (0.41) FDPSFDFT1SMN1; SMN2HCAR3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 FDPS 2048/4885FDFT1 2472/4885SMN1; SMN2 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.